Dr. Teera reveals that the US FDA has approved the use of the Bivalen vaccine as the main component for the American people instead of the original vaccine, the first dose – the booster dose. It can reduce the risk of severe illness by 16 times and reduce the risk of death by 13 times compared to the unvaccinated group.
On January 27, Dr. Thira Worathanarat, Faculty of Medicine Chulalongkorn University Posted a message via Facebook, stating that yesterday, around the world, there were 147,330 more people, 744 more deaths, a total of 674,168,661 people, and a total of 6,753,161 deaths.
The top 5 most infected are Japan, South Korea, Taiwan, the United States and Russia.
As of yesterday, in the number of new infections, countries from Europe and Asia occupied seven of the top 10 and 16 of the top 20 globally.
The number of new infections per day around the world right now from Asia and Europe together representing 90.72 percent of the whole world, while the number of deaths accounted for 82.39 percent
…Update US FDA meeting
A key meeting was held last night about the VRBPAC committee’s public vaccination plan.
Meeting almost six o’clock in America. or six o’clock in the morning of Thailand today
In essence, the judges voted 21:0 in favor of the bivalent vaccine (containing the original strain along with the BA.4/5 strain) as the main component of vaccines offered to the American population. It will replace the traditional vaccine from the first dose to the booster.
The information presented suggests that Those who received the bivalent vaccine had a 16-fold reduction in the risk of severe illness and a 13-fold reduction in the risk of death compared to the unvaccinated group.
And those who received the bivalent vaccine had a threefold reduction in the risk of severe illness and a twofold reduction in the risk of death compared to those who received the vaccine without the booster dose of the bivalent vaccine.
Another key point that will come up at the meeting is Discussion of future vaccination guidelines how to do There is a draft proposal for consideration according to the news the other day that it will offer once a year injections for people who have received the vaccine before (Figure 1), but it is concluded that VRBPAC has not yet been decided and it is expected that VRBPAC will Let the Advisory Committee on Immunization Practices of the US CDC reconsider.
the above movement This reflects the view that the bivalent vaccine will be the main preventative that will be used in the prevention of COVID-19. And in the future, vaccines will be updated according to the predicted substrains to be suitable for the epidemic strains. As for the long-term booster vaccination, it is unclear. Need to continue to follow each other
…Long COVID update
Landry M and colleagues from George Washington University, USA. Publication of research results in the March 2023 issue of the Journal of Infectious Diseases Emerging Infectious Diseases studied from July 2021 to March 2022 among 1,338 students, faculty members and university personnel who were infected with COVID-19. More than a third (36%) of people are experiencing Long COVID.
Long COVID problems are most common among people who are infected with symptoms. and/or have multiple symptoms, people with underlying diseases, women, people who haven’t received all the vaccines, people who smoke or have smoked before It was also found that complete booster vaccination It will reduce the risk of Long COVID by about half. Compared with the group that did not receive the booster vaccine. or groups that have not been vaccinated
…For Thailand, we
protection against infection or re-infection is the best
Wearing a mask correctly and consistently during daily life outside the home It will greatly reduce the risk.
refer
1. Vaccines and Related Biological Products Advisory Committee January 26, 2023 Meeting. US FDA
2. Live blog: Tracking the meeting of the FDA advisory panel on Covid vaccines. STAT News. 27 January 2023
3. FDA Advisory Committee Votes to Unify the Strain Composition of COVID-19 Primary and Booster Vaccines. Contagion Live. 27 January 2023
4. Landry M et al. Postacute Sequelae of SARS-CoV-2 in University Setting. Emerging Infectious Diseases. Volume 29, Number 3—March 2023